RT Journal Article
SR Electronic
T1 Global genomic surveillance of monkeypox virus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.15.24312031
DO 10.1101/2024.08.15.24312031
A1 Otieno, James R.
A1 Ruis, Christopher
A1 Onoja, Bernard A.
A1 Kuppalli, Krutika
A1 Hoxha, Ana
A1 Nitsche, Andreas
A1 Brinkmann, Annika
A1 Michel, Janine
A1 Mbala-Kisengeni, Placide
A1 Mukadi-Bamuleka, Daniel
A1 Osman, Muntasir Mohammed
A1 Hussein, Hanadi Elawad
A1 Raja, Muhammad Ali
A1 Fotsing, Richard
A1 Herring, Belinda L.
A1 Keita, Mory
A1 Rico, Jairo Mendez
A1 Gresh, Lionel
A1 Barakat, Amal
A1 Katawera, Victoria
A1 Nahapetyan, Karen
A1 Naidoo, Dhamari
A1 Floto, R. Andres
A1 Cunningham, Jane
A1 Van Kerkhove, Maria D.
A1 Lewis, Rosamund
A1 Subissi, Lorenzo
YR 2024
UL http://medrxiv.org/content/early/2024/08/20/2024.08.15.24312031.abstract
AB Monkeypox virus (MPXV) is endemic in Western and Central Africa and, in May 2022, a clade IIb lineage (B.1) caused a global outbreak outside Africa, resulting in its detection in 117 countries/territories. To understand the global phylogenetics of MPXV, we carried out the first analysis of all available MPXV sequences, including 10,670 sequences from 65 countries collected between 1958 and 2024. Our analysis reveals high mobility of clade I viruses within Central Africa, sustained human-to-human transmission of clade IIb lineage A viruses within the Eastern Mediterranean region, and distinct mutational signatures that can distinguish sustained human-to-human from animal-to-animal transmission. Moreover, distinct clade I sequences from Sudan suggest local MPXV circulation in areas of Eastern Africa over the past four decades. Our study underscores the importance of genomic surveillance in tracking spatiotemporal dynamics of MXPV clades and the need to strengthen such surveillance, including in some parts of Eastern Africa.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes